logo
logo
Guardian Pharmacy Services, Inc.

Guardian Pharmacy Services, Inc.

NYSE•GRDN
CEO: Mr. Fred P. Burke
セクター: Healthcare
業種: Medical - Distribution
上場日: 2016-04-21
Guardian Pharmacy Services, Inc., a pharmacy service company, provides a suite of technology-enabled services designed to help residents of long-term health care facilities (LTCFs) in the United States. Its individualized clinical, drug dispensing, and administration capabilities are used to serve the needs of residents in lower acuity LTCFs, such as assisted living facilities and behavioral health facilities and group homes. The company's Guardian Compass includes dashboards created using data from its data warehouse to help its local pharmacies plan, track, and optimize their business operations; and GuardianShield Programs for LTCFs. The company was founded in 2003 and is based in Atlanta, Georgia.
連絡先情報
300 Galleria Parkway SE, Suite 800, Atlanta, GA, 30339, United States
404-810-0089
guardianpharmacy.com
時価総額
$2.12B
PER (TTM)
51.7
32.5
配当利回り
--
52週高値
$37.43
52週安値
$17.78
52週レンジ
80%
順位30Top 19.5%
5.1
F-Score
改良版 Piotroski 分析
7年ファンダメンタル
堅調 • 5.1 / 9 ポイント
スコアレンジ (0-9)
8-9: 価値が優れている
6-7: 基礎体質が強い
4-5: 全体的に堅調
0-3: パフォーマンスが弱い
データ期間: 2019-2025

財務ダッシュボード

Q3 2025 データ

売上高

$377.43M+20.05%
直近4四半期の推移

EPS

$0.16-108.00%
直近4四半期の推移

フリーCF

$22.96M-414.94%
直近4四半期の推移

2025 Q3 決算ハイライト

主なハイライト

Nine-Month Revenue Growth Nine-month revenue $1.051B USD, up 18.1% driven by $110.0M organic growth and $51.2M from Acquisitions.
Profitability Turnaround Achieved Net income attributable to GPSI $28.3M USD, reversing prior $122.0M loss for nine months ended September 30.
SG&A Expenses Significantly Lower SG&A expenses $165.3M USD, down 35.7% for nine months, driven by reduced share-based compensation recognition.
Strong Operating Cash Flow Operating cash flow provided $65.7M USD for nine months, up $30.0M compared to the corresponding prior period.

リスク要因

Stock Price Volatility Risk Class A common stock price subject to substantial volatility; future dilution risk exists from conversion schedules and outstanding awards.
Acquisition Contingent Liability Contingent consideration liability stands at $3.35M USD; successful integration of recent acquisitions remains critical for performance.
Legal and Compliance Exposure Exposure to legal proceedings and claims arising in ordinary course of business; legal expenses totaled $4.5M USD for nine months.
Prior Period Comparison Skew Prior period SG&A heavily impacted by $128.0M USD share-based expense from RSU modification, affecting comparability analysis.

見通し

Targeted Growth Strategy Core growth strategy focuses on increasing resident count via organic expansion and acquiring pharmacies in attractive ALF and BHF sectors.
Sufficient Liquidity Position Existing cash and credit facility expected to meet working capital needs over next 12 months, though capital may be required.
New Accounting Adoption Adopted ASU 2023-07 regarding segment reporting effective January 1, 2024, requiring retrospective application for disclosures.

同業比較

売上高 (TTM)

STAAR Surgical CompanySTAA
$94.91B
+30136.8%
QuidelOrtho CorporationQDEL
$2.73B
-1.9%
Teladoc Health, Inc.TDOC
$2.53B
-2.4%

粗利益率 (最新四半期)

Janux Therapeutics, Inc.JANX
95.0%
-5.0pp
STAAR Surgical CompanySTAA
82.2%
+17.6pp
Harmony Biosciences Holdings, Inc.HRMY
75.1%
-1.9pp

主要指標

銘柄コード
時価総額
PER (TTM)
ROE (TTM)
負債比率
EWTX$3.18B-20.1-30.9%0.7%
TWST$3.01B-39.2-16.6%28.8%
NHC$2.63B26.010.0%8.1%

長期トレンド

直近4四半期
売上高
純利益
営業キャッシュフロー
4四半期売上高CAGR
3.7%
緩やかな成長
4四半期純利益CAGR
-6.3%
収益性の低下
キャッシュフロー安定性
100%
優れたキャッシュフローの実績

深度リサーチ

次回決算:2026年3月11日
|
EPS:$0.27
|
売上高:$390.04M
財務レポート
財務データ
全年度

  • Form 10-Q - Q3 2025

    会計期末: 2025年9月30日|提出日: 2025年11月10日|
    売上高: $377.43M+20.0%
    |
    EPS: $0.16-108.0%
    予想を下回る

  • Form 10-Q - Q2 2025

    会計期末: 2025年6月30日|提出日: 2025年8月11日|
    売上高: $344.33M+14.8%
    |
    EPS: $0.15-11.8%
    予想を下回る

  • Form 10-Q - Q1 2025

    会計期末: 2025年3月31日|提出日: 2025年5月12日|
    売上高: $329.31M+19.6%
    |
    EPS: $0.15-150.0%
    予想を下回る

  • Form 10-K - FY 2024

    会計期末: 2024年12月31日|提出日: 2025年3月26日|
    売上高: $1.23B+17.4%
    |
    EPS: $-1.77-553.8%
    予想を下回る

  • Form 10-Q - Q3 2024

    会計期末: 2024年9月30日|提出日: 2024年11月12日|
    売上高: $314.39M+19.7%
    |
    EPS: $-2.00+952.6%
    予想を下回る